Unknown

Dataset Information

0

Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.


ABSTRACT: More effective, less toxic treatments for recurrent ovarian cancer are needed. Although more than 60% of ovarian cancers express the estrogen receptor (ER), ER-targeted drugs have been disappointing due to drug resistance. In other estrogen-sensitive cancers, estrogen activates Src to phosphorylate p27 promoting its degradation and increasing cell-cycle progression. Because Src is activated in most ovarian cancers, we investigated whether combined Src and ER blockade by saracatinib and fulvestrant would circumvent antiestrogen resistance.ER and Src were assayed in 338 primary ovarian cancers. Dual ER and Src blockade effects on cell cycle, ER target gene expression, and survival were assayed in ER?+ ovarian cancer lines, a primary human ovarian cancer culture in vitro, and on xenograft growth.Most primary ovarian cancers express ER. Src activity was greater in ovarian cancer lines than normal epithelial lines. Estrogen activated Src, ER-Src binding, and ER translocation from cytoplasm to nucleus. Estrogen-mediated mitogenesis was via ER?, not ER?. While each alone had little effect, combined saracatinib and fulvestrant increased p27 and inhibited cyclin E-Cdk2 and cell-cycle progression. Saracatinib also impaired induction of ER-target genes c-Myc and FOSL1; this was greatest with dual therapy. Combined therapy induced autophagy and more effectively inhibited ovarian cancer xenograft growth than monotherapy.Saracatinib augments effects of fulvestrant by opposing estrogen-mediated Src activation and target gene expression, increasing cell-cycle arrest, and impairing survival, all of which would oppose antiestrogen resistance in these ER+ ovarian cancer models. These data support further preclinical and clinical evaluation of combined fulvestrant and saracatinib in ovarian cancer.

SUBMITTER: Simpkins F 

PROVIDER: S-EPMC3698880 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.

Simpkins Fiona F   Hevia-Paez Pedro P   Sun Jun J   Ullmer Wendy W   Gilbert Candace A CA   da Silva Thiago T   Pedram Ali A   Levin Ellis R ER   Reis Isildinha M IM   Rabinovich Brian B   Azzam Diana D   Xu Xiang-Xi XX   Ince Tan A TA   Yang Ji-Yeon JY   Verhaak Roel G W RG   Lu Yiling Y   Mills Gordon B GB   Slingerland Joyce M JM  

Clinical cancer research : an official journal of the American Association for Cancer Research 20120815 21


<h4>Purpose</h4>More effective, less toxic treatments for recurrent ovarian cancer are needed. Although more than 60% of ovarian cancers express the estrogen receptor (ER), ER-targeted drugs have been disappointing due to drug resistance. In other estrogen-sensitive cancers, estrogen activates Src to phosphorylate p27 promoting its degradation and increasing cell-cycle progression. Because Src is activated in most ovarian cancers, we investigated whether combined Src and ER blockade by saracatin  ...[more]

Similar Datasets

| S-EPMC7016006 | biostudies-literature
| S-EPMC3459133 | biostudies-literature
2014-07-22 | E-MTAB-887 | biostudies-arrayexpress